BIOCRYST PHARMACEUTICALS, INC. Shareholders' Equity
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Shareholders' Equity of -$454.29 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent -$454.29M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$553.84M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$119.15M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$387.89M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$454.29M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$553.84M 10-Q · filed 2026-08-05 |
| 2025-12-31 | -$119.15M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$387.89M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$421.59M 10-Q · filed 2026-08-05 |
| 2025-03-31 | -$451.93M 10-Q · filed 2026-08-05 |
| 2024-12-31 | -$475.93M 10-Q · filed 2026-08-05 |
| 2024-09-30 | -$468.56M 10-Q · filed 2025-11-04 |
| 2024-06-30 | -$475.61M 10-Q · filed 2025-11-04 |
| 2024-03-31 | -$476.17M 10-Q · filed 2025-11-04 |
| 2023-12-31 | -$455.53M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$410.99M 10-Q · filed 2024-11-05 |
| 2023-06-30 | -$388.71M 10-Q · filed 2024-11-05 |
| 2023-03-31 | -$328.29M 10-Q · filed 2024-11-05 |
| 2022-12-31 | -$294.60M 10-K · filed 2026-02-26 |
| 2022-09-30 | -$242.66M 10-Q · filed 2023-11-08 |
| 2022-06-30 | -$213.23M 10-Q · filed 2023-11-08 |
| 2022-03-31 | -$164.22M 10-Q · filed 2023-11-08 |
| 2021-12-31 | -$106.99M 10-K · filed 2025-02-25 |
| 2021-09-30 | -$147.04M 10-Q · filed 2022-11-04 |
| 2021-06-30 | -$106.08M 10-Q · filed 2022-11-04 |
| 2021-03-31 | -$74.99M 10-Q · filed 2022-11-04 |
| 2020-12-31 | -$19.26M 10-K · filed 2024-02-27 |
| 2020-09-30 | $33.64M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $76.51M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $3.65M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $38.25M 10-K · filed 2023-02-27 |
| 2019-09-30 | -$41.25M 10-Q · filed 2020-11-06 |
| 2019-06-30 | -$9.19M 10-Q · filed 2020-11-06 |
| 2019-03-31 | $22.51M 10-Q · filed 2020-11-06 |
| 2018-12-31 | $49.23M 10-K · filed 2022-02-28 |
| 2018-09-30 | $72.87M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $46.18M 10-Q · filed 2019-11-08 |
| 2018-03-31 | $62.05M 10-Q · filed 2019-11-08 |
| 2017-12-31 | $83.77M 10-K · filed 2021-03-01 |
| 2017-09-30 | $100.63M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $24.08M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $38.53M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $1.58M 10-K · filed 2020-03-13 |
| 2016-09-30 | $3.99M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $13.39M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $27.80M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $47.72M 10-K · filed 2019-03-14 |
| 2015-09-30 | $64.05M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $76.09M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $64.37M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $75.64M 10-K · filed 2018-03-12 |
| 2014-09-30 | $83.45M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $90.09M 10-Q · filed 2014-08-08 |
| 2014-03-31 | -$5.72M 10-Q · filed 2014-05-09 |
| 2013-12-31 | -$1.13M 10-K · filed 2017-02-27 |
| 2013-09-30 | $3.41M 10-Q · filed 2013-11-08 |
| 2013-06-30 | -$9.05M 10-Q · filed 2013-08-08 |
| 2013-03-31 | -$2.84M 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$454.00K 10-K · filed 2016-02-26 |
| 2012-09-30 | $9.78M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $15.66M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $23.15M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $14.81M 10-K · filed 2015-03-02 |
| 2011-09-30 | $26.04M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $39.27M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $65.50M 10-K · filed 2014-03-10 |
| 2009-12-31 | $86.27M 10-K · filed 2013-03-11 |
| 2008-12-31 | $46.43M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |